Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide effects on satiety, metabolic responses, and brain activation in type 2 diabetes
2007-005534-36Phase 4Completed
- Sponsor
- King's College Hospital
- Start
- Dec 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4 trial of exenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by King's College Hospital. Primary endpoint: Regional brain activation in response to food ingestion. Started Dec 2007; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-005534-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005534-36.